Axsome Therapeutics, Inc. (AXSM)
Stock Price:
$81.43 USD
3.36 (4.30%)
Updated Aug 10, 2020 11:10 AM EDT - Market open
Key Info
| Market Cap |
3.02B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-90.19M |
| Shares Out |
37.08M |
| EPS (ttm) |
-2.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$81.43 |
| Previous Close |
$78.07 |
| Change ($) |
3.36 |
| Change (%) |
4.30% |
| Day's Open |
79.03 |
| Day's Range |
76.35 - 81.50 |
| Day's Volume |
202,584 |
| 52-Week Range |
13.64 - 109.94 |
More Stats
| Market Cap |
3.02B |
| Enterprise Value |
2.84B |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.08M |
| Float |
27.18M |
| EPS (basic) |
-2.57 |
| EPS (diluted) |
-2.58 |
| FCF / Share |
-1.62 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.86M |
| Short Ratio |
6.32 |
| Short % of Float |
13.41% |
| Beta |
2.96 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
18.53 |
| Revenue |
n/a |
| Operating Income |
-89.32M |
| Net Income |
-90.19M |
| Free Cash Flow |
-60.17M |
| Net Cash |
177.20M |
| Net Cash / Share |
4.78 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-40.84% |
| ROE |
-103.95% |
| ROIC |
-344,347.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
9 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$162.22*
(99.21% upside)
Low
115
Current: $81.43
High
210
Target: 162.22
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -67.25 | -32.85 | -27.16 | -27.54 | -9.20 | -5.67 | -1.84 |
| Net Income | -68.35 | -30.97 | -28.94 | -27.20 | -12.21 | -6.00 | -2.17 |
| Shares Outstanding | 34.02 | 26.88 | 22.76 | 19.15 | 11.95 | 9.10 | 7.69 |
| Earnings Per Share | -2.01 | -1.15 | -1.27 | -1.42 | -1.02 | -0.66 | -0.28 |
| Operating Cash Flow | -46.38 | -30.05 | -26.47 | -21.28 | -7.44 | -4.60 | -1.63 |
| Capital Expenditures | -0.02 | -0.03 | -0.01 | -0.10 | -0.02 | - | - |
| Free Cash Flow | -46.39 | -30.09 | -26.48 | -21.39 | -7.46 | -4.60 | -1.63 |
| Cash & Equivalents | 220 | 13.97 | 34.02 | 36.62 | 48.04 | 2.62 | 2.09 |
| Total Debt | 19.93 | 6.91 | 9.93 | 9.74 | - | 4.48 | 3.83 |
| Net Cash / Debt | 200 | 7.06 | 24.09 | 26.88 | 48.04 | -1.87 | -1.74 |
| Assets | 221 | 15.38 | 35.56 | 38.21 | 49.08 | 2.79 | 2.10 |
| Liabilities | 41.83 | 14.44 | 18.84 | 16.64 | 2.63 | 5.99 | 4.13 |
| Book Value | 179 | 0.94 | 16.72 | 21.57 | 46.44 | -3.20 | -2.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Axsome Therapeutics, Inc. |
| Country |
United States |
| Employees |
45 |
| CEO |
Herriott Tabuteau |
Stock Information
| Ticker Symbol |
AXSM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AXSM |
| IPO Date |
November 19, 2015 |
Description
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.